The Aminophylline market is expected to register a CAGR of 2% during the forecast period. This is attributing to increasing incidences of a respiratory disorder, rise in demand for cost-effective treatment. Aminophylline is caffeine-like drugs also known as bronchodilators used for the treatment of respiratory diseases such as Asthma and Chronic obstructive pulmonary diseases. As respiratory diseases are one of the leading causes of death according to World Health Organization (WHO), aminophylline drugs help in diagnosing the population with these disorders. Moreover, Rapid innovation in the field of personalized medicines with technological advancements will also propel the Aminophylline market. As Aminophylline is widely used in a patient experiencing acute exacerbations of COPD leading to boost the market. Furthermore, as per Global Asthma report, in 2018 with the growing number of chronic respiratory disease patients affecting more than one billion people globally, hence results in the adoption of these drugs combination for diagnosis and treatment and then boosts the Aminophylline market.
Key Market Trends
Chronic Obstructive Pulmonary Disease (COPD) segment in Aminophylline Market is Expected to Witness a Healthy Growth in Future.
Chronic Obstructive Pulmonary Disease is expected to witness healthy growth in the future owing to the growing number of respiratory disorders and infections worldwide. COPD is a type of lung disease that blocks airflow and makes it difficult to breathe. Aminophylline helps in improving the contraction of the diaphragm and protecting the airway from irritant along with anti-inflammatory actions by relaxing lung muscles, thus helps in diagnosing the respiratory diseases. The rising number of the patient pool leading to the adoption of these drugs combination and further drives the segment growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant market share in the global Aminophylline market due to the increasing aging population, rising lung diseases, the introduction of new drugs, technological advancements, increasing healthcare expenditure and the presence of well-established healthcare infrastructure. The Global Burden of Disease Study reports a prevalence of 251 million cases of COPD globally in 2016. This incidence of respiratory disorders is leading to promotes the growth of the Aminophylline market.
The Aminophylline market is moderately competitive and consists of several international as well as local players. Some of the companies which are currently dominating the market are Pfizer Inc., Omega Laboratories, Merck KGaA, Torque Pharma, Endo International, AGP Limited and ACTIZA PHARMACEUTICAL.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increase in Incidence of Respiratory Disorders
4.2.2 Rise in Demand of Cost Effective Treatment
4.3 Market Restraints
4.3.1 Side Effects of the Drug
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.2 By Applications
5.2.1 Chronic Obstructive Pulmonary Disease (COPD)
5.2.3 Infant Apnea
5.3 By End User
5.3.3 Ambulatory Surgical Centers
5.4.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.4.5 South America
126.96.36.199 Rest of South America
6.1.1 Pfizer Inc.
6.1.2 Omega Laboratories
6.1.3 Merck KGaA
6.1.5 Endo International
6.1.6 AGP Limited
6.1.7 ACTIZA PHARMACEUTICAL
A selection of companies mentioned in this report includes:
- Pfizer Inc.
- Omega Laboratories
- Merck KGaA
- Endo International
- AGP Limited
- ACTIZA PHARMACEUTICAL